Literature DB >> 15591457

Immunohistochemical evaluation of thymidylate synthase (TS) and p16INK4a in advanced colorectal cancer: implication of TS expression in 5-FU-based adjuvant chemotherapy.

Shingo Kamoshida1, Hiroshi Matsuoka, Taro Ishikawa, Kotaro Maeda, Ryoichi Shimomura, Ken-ichi Inada, Yutaka Tsutsumi.   

Abstract

BACKGROUND: Our previous analyses on the expression of thymidylate synthase (TS) and p16(INK4a) in colorectal cancer patients administered 5-fluorouracil (5-FU) pre-operatively demonstrated that a high level of TS expression was a predictor of 5-FU resistance, and that the combination of a low level of TS expression and induction of p16(INK4a) after chemotherapy implicated chemosensitivity. The present study aimed to assess the relationship between the biological behavior of advanced colorectal cancer treated post-operatively by 5-FU-based chemotherapy and the expression of TS and p16(INK4a) in primary tumors.
METHODS: Formalin-fixed, paraffin-embedded specimens from 132 colorectal cancers (Dukes' B, 36 cases; Dukes' C, 60 cases; and Dukes' D, 36 cases) treated by 5-FU post-operatively were immunostained for TS and p16(INK4a). Antigenicities were suitably retrieved.
RESULTS: Primary tumors expressing high levels of TS in the Dukes' C group showed a significantly shorter recurrence-free interval (RFI) (P = 0.0002). The overall survival (OS) was shorter in high TS expressors than in low TS expressors (P = 0.001). A high level of TS expression also correlated with advanced Dukes' staging and the severity of nodal metastasis (Dukes' B versus Dukes' D, P = 0.001; Dukes' C versus Dukes' D, P = 0.008; N0 versus N2, P = 0.002; N1 versus N2, P = 0.03). p16(INK4a) expression was not correlated with the prognosis or clinicopathological features.
CONCLUSIONS: Appropriate immunohistochemical evaluation is essentially important. We suggest that, in the Dukes' C group, a 5-FU-based regimen can be chosen as a first-line chemotherapy for low TS expressors. TS-high cancer should be treated with anti-cancer agents acting through different mechanisms. Further research should be conducted on applying TS immunostaining to the treatment strategy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15591457     DOI: 10.1093/jjco/hyh113

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  11 in total

1.  B7-H3 increases thymidylate synthase expression via the PI3k-Akt pathway.

Authors:  Bo Jiang; Fen Liu; ZhiHui Liu; Ting Zhang; Dong Hua
Journal:  Tumour Biol       Date:  2016-01-20

2.  Thymidylate Synthase Overexpression Drives the Invasive Phenotype in Colon Cancer Cells.

Authors:  Wojciech M Ciszewski; Małgorzata Chmielewska-Kassassir; Lucyna A Wozniak; Katarzyna Sobierajska
Journal:  Biomedicines       Date:  2022-05-29

3.  Nuclear thymidylate synthase expression in sporadic colorectal cancer depends on the site of the tumor.

Authors:  Violetta Sulzyc-Bielicka; Pawel Domagala; Ewa Majdanik; Maria Chosia; Dariusz Bielicki; Jozef Kladny; Mariusz Kaczmarczyk; Krzysztof Safranow; Wenancjusz Domagala
Journal:  Virchows Arch       Date:  2009-05-15       Impact factor: 4.064

4.  Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer.

Authors:  Kotaro Miyake; Satoru Imura; Tomoharu Yoshizumi; Tetsuya Ikemoto; Yuji Morine; Mitsuo Shimada
Journal:  Int J Clin Oncol       Date:  2007-04-27       Impact factor: 3.402

5.  Prognostic and predictive value of thymidylate synthase expression in colon cancer.

Authors:  Gerasimos Tsourouflis; Stamatios E Theocharis; Anastasia Sampani; Athina Giagini; Alkiviadis Kostakis; Gregory Kouraklis
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

6.  Correlation between expression of thymidylate synthase and clinical outcome of advanced gastric cancer treated with capecitabine alone chemotherapy.

Authors:  Xin Fu Liu; Hui Zhang; Jian Qun Sun; Chan Yin; Teng Fei Liu; Hua Yang; Long Hua Chen
Journal:  Tumour Biol       Date:  2014-09-04

7.  Novel strategy with gemcitabine for advanced pancreatic cancer.

Authors:  Shuji Komori; Shinji Osada; Kazuhiro Yoshida
Journal:  ISRN Oncol       Date:  2011-05-23

8.  Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer.

Authors:  S Kamoshida; M Suzuki; R Shimomura; Y Sakurai; Y Komori; I Uyama; Y Tsutsumi
Journal:  Br J Cancer       Date:  2007-01-09       Impact factor: 7.640

9.  Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer.

Authors:  M Gusella; A C Frigo; C Bolzonella; R Marinelli; C Barile; A Bononi; G Crepaldi; D Menon; L Stievano; S Toso; F Pasini; E Ferrazzi; R Padrini
Journal:  Br J Cancer       Date:  2009-04-21       Impact factor: 7.640

10.  Thymidylate synthase expression and p21(WAF1)/p53 phenotype of colon cancers identify patients who may benefit from 5-fluorouracil based therapy.

Authors:  Violetta Sulzyc-Bielicka; Pawel Domagala; Dariusz Bielicki; Krzysztof Safranow; Wenancjusz Domagala
Journal:  Cell Oncol (Dordr)       Date:  2013-11-26       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.